Cargando…

Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials

OBJECTIVE: This study was undertaken to evaluate safety/tolerability and efficacy of adjunctive brivaracetam (BRV) in patients on one or two concomitant antiseizure medications (ASMs) and in patients on one specific concomitant ASM. METHODS: Post hoc analysis was made of double‐blind trials (N01252/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ryvlin, Philippe, Dimova, Svetlana, Elmoufti, Sami, Floricel, Florin, Laloyaux, Cédric, Nondonfaz, Xavier, Biton, Victor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541390/ https://www.ncbi.nlm.nih.gov/pubmed/35582748 http://dx.doi.org/10.1111/epi.17304

Ejemplares similares

Time course of 75%–100% efficacy response of adjunctive brivaracetam
por: Klein, Pavel, et al.
Publicado: (2020)

Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures
por: Lattanzi, Simona, et al.
Publicado: (2022)

Economic Value of Adjunctive Brivaracetam Treatment Strategy for Focal Onset Seizures in Finland
por: Väätäinen, Saku, et al.
Publicado: (2019)

Adjunctive Brivaracetam in Older Patients with Focal Seizures: Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST)
por: Lattanzi, Simona, et al.
Publicado: (2022)

Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records
por: Villanueva, Vicente, et al.
Publicado: (2023)

Brivaracetam: a novel antiepileptic drug for focal-onset seizures
por: Stephen, Linda J., et al.
Publicado: (2017)

Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)
por: Lattanzi, Simona, et al.
Publicado: (2021)

Post hoc analysis of a phase 3, multicenter, open‐label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications
por: Rosenfeld, William E., et al.
Publicado: (2021)

Correction to: Adjunctive Brivaracetam in Focal Epilepsy: Real‑World Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST)
por: Lattanzi, Simona, et al.
Publicado: (2021)

Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies
por: Ben-Menachem, Elinor, et al.
Publicado: (2016)

Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam
por: Mukuria, Clara, et al.
Publicado: (2016)

Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures
por: Mumoli, Laura, et al.
Publicado: (2015)

Extrapolation of a Brivaracetam Exposure–Response Model from Adults to Children with Focal Seizures
por: Schoemaker, Rik, et al.
Publicado: (2017)

Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis
por: Lattanzi, Simona, et al.
Publicado: (2022)

Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures
por: Farkas, Viktor, et al.
Publicado: (2019)

Efficacy and tolerability of brivaracetam monotherapy in childhood and juvenile absence epilepsy: An innovative adaptive trial design
por: Bast, Thomas, et al.
Publicado: (2022)

Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures [Corrigendum]
Publicado: (2015)

Comparative antiseizure medications of adjunctive treatment for children with drug-resistant focal-onset seizures: A systematic review and network meta-analysis
por: Zhang, Lanlan, et al.
Publicado: (2022)

Brivaracetam as Early Add-On Treatment in Patients with Focal Seizures: A Retrospective, Multicenter, Real-World Study
por: Lattanzi, Simona, et al.
Publicado: (2022)

Long‐term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program
por: Sander, Josemir W., et al.
Publicado: (2021)

Clinical and Electroencephalography Assessment of the Effects of Brivaracetam in the Treatment of Drug-Resistant Focal Epilepsy
por: Savastano, Ersilia, et al.
Publicado: (2021)

Intravenous Brivaracetam in the Management of Acute Seizures in the Hospital Setting: A Scoping Review
por: Lee, Kiwon, et al.
Publicado: (2022)

Noninvasive detection of focal seizures in ambulatory patients
por: Ryvlin, Philippe, et al.
Publicado: (2020)

Long‐term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11‐year, open‐label, follow‐up trial
por: O’Brien, Terence J., et al.
Publicado: (2020)

Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients < 16 Years with Epilepsy: An Open-Label Trial
por: Liu, Edwin, et al.
Publicado: (2019)

Forgetting to take antiseizure medications is associated with focal to bilateral tonic-clonic seizures, as revealed by a cross-sectional study
por: Suzuki, Hime, et al.
Publicado: (2020)

Critical Appraisal of Cenobamate as Adjunctive Treatment of Focal Seizures in Adults
por: Zaccara, Gaetano, et al.
Publicado: (2021)

Comparative Economic Outcomes in Patients with Focal Seizure Initiating First-Line Eslicarbazepine Acetate Monotherapy versus Generic Antiseizure Drugs
por: Mehta, Darshan, et al.
Publicado: (2021)

Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes
por: French, Jacqueline, et al.
Publicado: (2016)

Brivaracetam in treating epileptic encephalopathy and refractory focal epilepsies in patients under 14 years of age
por: RUSSO, Angelo, et al.
Publicado: (2021)

Clinical and Economic Outcomes of Intravenous Brivaracetam Compared With Levetiracetam for the Treatment of Seizures in United States Hospitals
por: Beaty, Silky, et al.
Publicado: (2021)

Acute and long‐term effects of brivaracetam and brivaracetam–diazepam combinations in an experimental model of status epilepticus
por: Niquet, Jerome, et al.
Publicado: (2017)

Capturing seizures in clinical trials of antiseizure medications for KCNQ2‐DEE
por: Millichap, John J., et al.
Publicado: (2021)

Commentary — Early discontinuation of antiseizure medication in neonatal seizures - Proceed with caution
por: Volpe, J.J.
Publicado: (2022)

Brivaracetam Retention Rate and Seizure Outcomes in Patients with Drug-Resistant Focal Epilepsy Included in the Medical Need Program in Belgium: A Real-World, Multicenter, Chart Review
por: Depondt, Chantal, et al.
Publicado: (2021)

Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures
por: Chung, Steve S., et al.
Publicado: (2020)

Loss of normal Alzheimer's disease-associated Presenilin 2 function alters antiseizure medicine potency and tolerability in the 6-Hz focal seizure model
por: Lehmann, Leanne M., et al.
Publicado: (2023)

Safety of Early Discontinuation of Antiseizure Medication After Acute Symptomatic Neonatal Seizures
por: Glass, Hannah C., et al.
Publicado: (2021)

Long-term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures
por: Klein, Pavel, et al.
Publicado: (2022)

Understanding the burden of focal epilepsy as a function of seizure frequency in the United States, Europe, and Brazil
por: Gupta, Shaloo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6d46hqgdrrfa7cf2uurf9krfj3